Speaker:

David A. Ahlquist, M.D.

Consultant – Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota

Professor of Medicine, Mayo Clinic College of Medicine and Science

Master’s Faculty Privileges in Clinical & Translational Science, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine and Sciences

Senior Scientific Advisory – EXACT Sciences, Madison, Wisconsin

President – Mayo Clinic Rochester Societies, Plummer Society, Mayo Clinic, Rochester Minnesota

Learning Objectives ~ Upon conclusion of this program, participants should be able to:

• Appraise the evidence supporting colorectal cancer screening by stool DNA, define its approved use, and review practice impact to date
• Identify gaps in our current approach to early detection of all cancer and glimpse emerging new molecular screening tools
• Examine the cancer screening paradigm and how it could be changed by non-invasive molecular technologies

Locations:    

• Mayo Clinic Building, Taylor Auditorium
• Mayo Clinic Hospital, MCH Waugh Auditorium Side A (MCH 1-220A)
• Mayo Clinic Primary Care, Phoenix Campus
• Mayo Clinic Women’s Health Internal Medicine
• Mayo Clinic Family Medicine – Arrowhead
• Kingman Regional Medical Center
• San Tan Medical Center
• Canyon Ranch Medical Center

ALL PHYSICIANS AND ALLIED STAFF ARE WELCOME

ATTENDANCE REQUIREMENT 
A unique presentation code must be sent via text to 507-200-3010 
to record attendance and to ensure you receive CME credit for your attendance.  
NOTE:  Attendees must be present to receive code.  

FACULTY DISCLOSURE

As a provider accredited by Accreditation Council on Continuing Medical Education (ACCME), Mayo Clinic College of Medicine and Science, must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships is included course materials so participants may formulate their own judgments regarding the presentation.